Ependymoma Treatment & Management

  • Author: Jeffrey N Bruce, MD; Chief Editor: Jules E Harris, MD   more...
 
Updated: Jan 13, 2012
 

Medical Care

Medical management of patients with ependymomas includes adjuvant therapy (ie, conventional radiation therapy, radiosurgery, chemotherapy), steroids for treatment of peritumoral edema, and anticonvulsants in patients with supratentorial ependymoma.[23, 24]

  • Adjuvant treatment of histologically confirmed intracranial ependymoma remains an actively debated topic.
  • The National Comprehensive Cancer Network (NCCN) suggests the following for adults: After a gross total resection (GTR) of an intracranial WHO grade II ependymoma, limited field fractionated external beam radiotherapy (LFFEBRT) can be considered versus mere observation. Postoperative LFFEBRT is recommended for WHO grade II ependymoma when subtotal resection is noted on postoperative MRI, and for grade III anaplastic ependymoma regardless of the extent of resection.[25] If postoperative spinal MRI or LP findings are positive, craniospinal radiation therapy is indicated regardless of grade or extent of resection. For recurrent ependymoma, the NCCN suggests that patients who have not received radiation therapy receive radiation therapy, and if a patient has received radiation therapy, then chemotherapy, radiation therapy, or supportive care should be considered.[26]
  • For children younger than 3 years, the use of chemotherapy has historically been fostered by the desire to avoid adverse radiation effects. Combination chemotherapy regimens comprising cisplatin, etoposide (VP-16), carboplatin, vincristine, and mechlorethamine, or ifosfamide, carboplatin, and etoposide (ICE), have been administered with variable success.
  • In older children and adults, radiotherapy is the standard treatment following resection for most patients with WHO grade II ependymoma. While surgery alone has been piloted for a very select group of patients (those with supratentorial tumors who undergo gross total resection with a wide resection margin), most tumors of the posterior fossa cannot be fully resected and are likely to recur without postoperative radiation.[27, 28]
  • Early attempts at defining appropriate treatment paradigms for intracranial ependymoma have depended heavily upon single-institution retrospective reviews.
  • In 1990, Goldwein and colleagues reviewed 36 children (aged 0.8-16.8 y) with recurrent intracranial ependymoma who were treated for a total of 52 separate relapses from 1970-1989.[29]
    • They concluded that some patients with histologically benign ependymoma at first relapse could benefit from aggressive therapy, with occasional long-term, progression-free survival possible. In contrast, patients with malignant lesions or patients who relapsed a second time were less likely to benefit from conventional therapy.
    • In their study, initial therapy for relapse consisted of surgery in 33 cases and chemotherapy in 38 cases. Twelve patients received radiation at the time of first relapse, and 5 of these 12 who initially had been treated with surgery and chemotherapy alone were irradiated to full dose.
    • The 2-year actuarial survival and progression-free survival rates were 29% and 23%, respectively. The 2-year survival rate after treatment of first relapse was 39%. Of the 52, 44 subsequent relapses (and 1 septic death) occurred, 3 of which occurred in the 5 patients treated with definitive radiation. Twenty-seven relapses occurred exclusively with local disease. Eight patients had relapse outside of as well as in the primary site. Survival rate was better for patients who had histologically benign lesions at relapse (53% vs 9%, P < 0.02), and for patients in the first versus subsequent relapse (P < 0.005). Cisplatin and VP-16 appeared to be the most active chemotherapeutic agents.
  • In 1992, Chiu and colleagues evaluated the clinical courses of 25 children aged 2 weeks to 15 years treated for intracranial ependymoma at M. D. Anderson Cancer Center.[30]
    • Nine patients had supratentorial primaries (5 high grade, 4 low grade), and 16 patients had infratentorial primaries (9 high grade, 7 low grade). Five patients underwent gross complete resection, and 20 patients had incomplete resection. Seven patients received craniospinal irradiation (25-36 Gy to the neuro-axis, 45-55 Gy to tumor bed), and 12 received local field irradiation (29-60 Gy, median 50 Gy). Five infants had adjuvant chemotherapy without radiotherapy, 6 children had postradiotherapy adjuvant chemotherapy, and 12 patients had salvage chemotherapy with various agents and number of courses.
    • Eight patients were alive, disease free, and without relapse from 1-12.5 years after diagnosis (median 42 mo). The primary failure pattern was local recurrence.
    • The data presented in this study suggested that the long-term cure rate of children with ependymoma is suboptimal; histologic grade may be of prognostic importance for supratentorial tumors; prognosis appears worse for girls and infants younger than 3 years; in well-staged patients, routine spinal irradiation could be omitted; and the role of adjuvant chemotherapy is unclear.
  • In 1998, an extensive review and analysis of all published literature on the topic of intracranial ependymoma highlighted the difficulty associated with extrapolating data from single-institution studies.[1]
    • Forty-five series were reviewed, including more than 1400 children. The largest series reported on 92 patients, and the accrual rate ranged from 0.32-12 patients per year. Notably, the extent of surgical resection was the only reported prognostic factor in these series that was consistently found to be a valid predictor of outcome.
    • These findings were confirmed by a prospectively randomized trial published that same year evaluating Children's Cancer Group Protocol 921. Predictors of long-term survival included an estimate of the extent of resection made at surgery (total compared with less than total, P =0.0001) and the amount of residual tumor on postoperative imaging as verified by centralized radiologic review. Other factors, including centrally reviewed tumor histopathologic type, location, metastasis, and tumor (M and T) stages, patient age, race, sex, and chemotherapy treatment regimen were not found to be correlated significantly with long-term survival.
  • More recently, in 2000, Stafford and colleagues evaluated the efficacy of stereotactic radiosurgery (SRS) for locally recurrent ependymoma and found that this technique may allow a high salvage rate in selected patients. In 12 patients (with a total of 17 tumors) treated with SRS, a medial survival of 3.4 years was achieved. In-field local control was achieved in 14 of the 17 tumor sites, and the estimated 3-year local control rate was 68%. Two patients developed treatment-related complications following therapy.[31]
  • Currently, no role exists for adjuvant therapy of spinal ependymoma after complete surgical resection. For patients who have postoperative residual tumor or early recurrence, radiation is considered on the basis of the individual patient's medical condition and neurological status.
  • Conventional chemotherapy has yet to effect any improvement in outcome for ependymoma,[32, 33] and radiotherapy to the developing brain is to be avoided due to its substantial neurocognitive effects. Therefore, recent emphasis has been placed on molecular subclassification of these tumors. hTERT negativity is associated with a 5-year survival rate of 84% compared to 41% for hTERT positive tumors.[34] Several genes have been identified as having associations with risk of relapse, age of onset, and location of tumor.[35, 36] As more information regarding molecular signatures of ependymomas is gathered, more individualized therapies may be realized.[8]
Next

Surgical Care

The extent of tumor resection is the most important prognostic factor associated with long-term survival for patients with nonmalignant forms of ependymoma, regardless of location. Thus, a gross total resection (GTR) is optimal.

  • Children with posterior fossa lesions usually undergo surgery via a midline suboccipital approach. Despite the survival advantage of GTR, lesions of the posterior fossa are in close proximity to cranial nerves making GTR risky and fraught with the possibility of long-term neurologic dysfunction and disability. Posterior fossa syndrome, also referred to as cerebellar mutism, is a recognized complication of posterior fossa surgery and most common when brainstem invasion is observed.[37, 38] Mutism can have a latency range of 1-7 days and duration of 6-365 days. Thus, consideration must be given to the balance between improved survival with GTR and potential postoperative morbidity.
    • Hydrocephalus can be managed with a perioperative external ventricular drain, ventriculoperitoneal shunt, or, more rarely, third ventriculostomy.
    • A reasonable algorithm of management affords the medical team the opportunity to assess the need for permanent CSF diversion after tumor resection. This can be accomplished by clamping the external ventricular drain postoperatively and monitoring intracranial pressure and/or clinical signs.
    • Although the approach to supratentorial lesions varies according to location, the goal of gross total resection should be the same as in infratentorial surgery.
  • Intramedullary tumors are approached via standard laminectomy with the patient in the prone position.
    • Although somatosensory evoked potentials and direct motor evoked potentials are employed routinely, only rarely do they influence surgical decisions or technique.
    • Laminoplasty is performed in children but does not guarantee long-term stability.
    • The strategies for intramedullary tumor removal depend upon the relationship of the tumor to the spinal cord. Most tumors are totally intramedullary and are not apparent upon inspection of the surface.
    • Intraoperative ultrasound may be used to localize the tumor and to determine the rostrocaudal tumor borders.
    • The extent of tumor resection is guided by the anatomy of the lesion, intraoperative monitoring, the surgeon's experience, and the preliminary frozen-section histologic diagnosis.
    • The plane between an ependymoma and surrounding spinal cord is usually well defined and easily developed.
    • Large tumors may require internal decompression with an ultrasonic aspirator or laser.
    • A competent dural closure is essential to prevent CSF leaks.
  • The role of surgery for filum terminale ependymoma depends on the size of the tumor and its relationship to the surrounding roots of the cauda equina.
    • Gross total en bloc resection should be attempted whenever possible. This usually can be accomplished for small and moderate-sized tumors, which remain well circumscribed within the fibrous coverings of the filum terminale and easily separable from the cauda equina nerve roots.
    • A portion of uninvolved filum terminale is generally present between the tumor and spinal cord.
    • Amputation of the afferent and efferent filum segments is required for tumor removal.
    • Internal decompression is not used for small and moderate-sized tumors because this may increase the risk of CSF dissemination.
    • Recurrences following successful en bloc resection are rare.
Previous
Next

Consultations

  • A team of specialists including a neurologist, neurosurgeon, neurooncologist, and radiation oncologist should evaluate patients with ependymomas to develop a coordinated treatment strategy.
  • Postoperative consultations should include physical therapy and rehabilitative medicine representatives to facilitate recovery.
Previous
Next

Diet

No restrictions of diet are required for patients with ependymomas.

Previous
Next

Activity

No universal restrictions on activity are required for patients with ependymomas.

  • Patients' activity depends on their overall neurological status.
  • In the case of patients with supratentorial ependymomas, a history of seizures may preclude operation of motor vehicles.
Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Jeffrey N Bruce, MD  Edgar M Housepian Professor of Neurological Surgery Research, Vice-Chairman and Professor of Neurological Surgery, Director of Brain Tumor Tissue Bank, Director of Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Columbia University College of Physicians and Surgeons

Jeffrey N Bruce, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Neurological Surgeons, American Society of Clinical Oncology, Congress of Neurological Surgeons, New York Academy of Sciences, North American Skull Base Society, Pituitary Society, Society for Neuro-Oncology, and Society of Neurological Surgeons

Disclosure: NIH Grant/research funds Other

Coauthor(s)

David J Fusco, MD  Resident Physician in Neurological Surgery, Barrow Neurosurgical Institute, St Joseph's Hospital and Medical Center

David J Fusco, MD is a member of the following medical societies: American Association of Neurological Surgeons, American Medical Association, Congress of Neurological Surgeons, and North American Spine Society

Disclosure: Nothing to disclose.

Neil A Feldstein, MD  Director of Pediatric Neurosurgery, Department of Neurosurgery, Babies and Children's Hospital of New York, Assistant Professor, Departments of Clinical Neurosurgery and Pediatrics, Columbia-Presbyterian Medical Center, Columbia University

Neil A Feldstein, MD is a member of the following medical societies: American Association of Neurological Surgeons, American Cleft Palate/Craniofacial Association, American College of Surgeons, American Medical Association, and Medical Society of the State of New York

Disclosure: Nothing to disclose.

Benjamin Kennedy  Columbia University College of Physicians and Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Robert C Shepard, MD, FACP  Associate Professor of Medicine in Hematology and Oncology at University of North Carolina at Chapel Hill; Vice President of Scientific Affairs, Therapeutic Expertise, Oncology, at PRA International

Robert C Shepard, MD, FACP is a member of the following medical societies: American Association for Cancer Research, American College of Physician Executives, American College of Physicians, American Federation for Clinical Research, American Federation for Medical Research, American Medical Association, American Medical Informatics Association, American Society of Hematology, Association of Clinical Research Professionals, Eastern Cooperative Oncology Group, European Society for Medical Oncology, Massachusetts Medical Society, and Society for Biological Therapy

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Rajalaxmi McKenna, MD, FACP  Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems

Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD  Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Immunologists, American Society of Hematology, and Central Society for Clinical Research

Disclosure: GlobeImmune Salary Consulting

Additional Contributors

We wish to acknowledge previous contributions to this article by Paul C McCormick, MD, and Allen Waziri, MD.

References

  1. Applegate GL, Marymont MH. Intracranial ependymomas: a review. Cancer Invest. 1998;16(8):588-93. [Medline].

  2. Schwartz TH, Kim S, Glick RS, et al. Supratentorial ependymomas in adult patients. Neurosurgery. Apr 1999;44(4):721-31. [Medline].

  3. Verma A, Zhou H, Chin S, Bruggers C, Kestle J, Khatua S. EGFR as a predictor of relapse in myxopapillary ependymoma. Pediatr Blood Cancer. Dec 20 2011;[Medline].

  4. Tripathy P, Mohapatra D, Mohapatra S. Primary intradural extramedullary ependymoma: report of two cases and review of the literature. Neurol Neurochir Pol. Jul-Aug 2011;45(4):397-401. [Medline].

  5. Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One. 2011;6(10):e25114. [Medline]. [Full Text].

  6. Son DW, Song GS, Han IH, Choi BK. Primary extramedullary ependymoma of the cervical spine : case report and review of the literature. J Korean Neurosurg Soc. Jul 2011;50(1):57-9. [Medline]. [Full Text].

  7. Poppleton H, Gilbertson RJ. Stem cells of ependymoma. Br J Cancer. Jan 15 2007;96(1):6-10. [Medline].

  8. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. Oct 2005;8(4):323-35. [Medline].

  9. Dal Cin P, Sandberg AA. Cytogenetic findings in a supratentorial ependymoma. Cancer Genet Cytogenet. Feb 1988;30(2):289-93. [Medline].

  10. Metzger AK, Sheffield VC, Duyk G, et al. Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci U S A. Sep 1 1991;88(17):7825-9. [Medline].

  11. Sainati L, Montaldi A, Putti MC, et al. Cytogenetic t(11;17)(q13;q21) in a pediatric ependymoma. Is 11q13 a recurring breakpoint in ependymomas?. Cancer Genet Cytogenet. Apr 1992;59(2):213-6. [Medline].

  12. Mazewski C, Soukup S, Ballard E, et al. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet. Aug 1999;113(1):1-8. [Medline].

  13. Nijssen PC, Deprez RH, Tijssen CC, et al. Familial anaplastic ependymoma: evidence of loss of chromosome 22 in tumour cells. J Neurol Neurosurg Psychiatry. Oct 1994;57(10):1245-8. [Medline].

  14. Yokota T, Tachizawa T, Fukino K, Teramoto A, Kouno J, Matsumoto K. A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor. J Hum Genet. 2003;48(11):598-602. [Medline].

  15. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol. Aug 1999;155(2):627-32. [Medline].

  16. Hulsebos TJ, Oskam NT, Bijleveld EH, Westerveld A, Hermsen MA, van den Ouweland AM. Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. Br J Cancer. Dec 1999;81(7):1150-4. [Medline].

  17. James CD, He J, Carlbom E, et al. Loss of genetic information in central nervous system tumors common to children and young adults. Genes Chromosomes Cancer. Jul 1990;2(2):94-102. [Medline].

  18. Yao Y, Mack SC, Taylor MD. Molecular genetics of ependymoma. Chin J Cancer. Oct 2011;30(10):669-81. [Medline].

  19. McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a Surveillance, Epidemiology, and End Results study. J Neurosurg. Dec 5 2008;[Medline].

  20. Bouffet E, Perilongo G, Canete A, Massimino M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol. Jun 1998;30(6):319-29; discussion 329-31. [Medline].

  21. Polednak AP, Flannery JT. Brain, other central nervous system, and eye cancer. Cancer. Jan 1 1995;75(1 Suppl):330-7. [Medline].

  22. Macdonald J. Advances in imaging techniques in neuroendocrine tumors: miscellaneous papers of interest. Curr Opin Oncol. Feb 1990;2(1):117-8. [Medline].

  23. Chamberlain MC, Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J Med. Feb 1998;168(2):114-20. [Medline].

  24. Merchant TE. Current management of childhood ependymoma. Oncology (Williston Park). 2002/05;16(5):629-42, 644; discussion 645-6, 648.

  25. Timmermann B, Kortmann RD, Kühl J, Meisner C, Slavc I, Pietsch T. Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys. Jan 15 2000;46(2):287-95. [Medline].

  26. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology: Adult Intracranial Ependymomas. Available at http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed Jan 2009.

  27. Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas?. J Neurosurg. Apr 2005;102(4):629-36. [Medline].

  28. Merchant TE, Li C, Xiong X, Gaber MW. Cytokine and Growth Factor Responses After Radiotherapy for Localized Ependymoma. Int J Radiat Oncol Biol Phys. Nov 17 2008;[Medline].

  29. Goldwein JW, Glauser TA, Packer RJ, et al. Recurrent intracranial ependymomas in children. Survival, patterns of failure, and prognostic factors. Cancer. Aug 1 1990;66(3):557-63. [Medline].

  30. Chiu JK, Woo SY, Ater J, et al. Intracranial ependymoma in children: analysis of prognostic factors. J Neurooncol. Jul 1992;13(3):283-90. [Medline].

  31. Stafford SL, Pollock BE, Foote RL, Gorman DA, Nelson DF, Schomberg PJ. Stereotactic radiosurgery for recurrent ependymoma. Cancer. Feb 15 2000;88(4):870-5. [Medline].

  32. Partap S, Fisher PG. Update on new treatments and developments in childhood brain tumors. Curr Opin Pediatr. Dec 2007;19(6):670-4. [Medline].

  33. Reni M, Gatta G, Mazza E, Vecht C. Ependymoma. Crit Rev Oncol Hematol. Jul 2007;63(1):81-9. [Medline].

  34. Tabori U, Ma J, Carter M, Zielenska M, Rutka J, Bouffet E, et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol. Apr 1 2006;24(10):1522-8. [Medline].

  35. Sowar K, Straessle J, Donson AM, Handler M, Foreman NK. Predicting which children are at risk for ependymoma relapse. J Neurooncol. May 2006;78(1):41-6. [Medline].

  36. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol. Nov 20 2006;24(33):5223-33. [Medline].

  37. Catsman-Berrevoets CE, Van Dongen HR, Mulder PG, et al. Tumour type and size are high risk factors for the syndrome of "cerebellar" mutism and subsequent dysarthria. J Neurol Neurosurg Psychiatry. Dec 1999;67(6):755-7. [Medline].

  38. Doxey D, Bruce D, Sklar F, et al. Posterior fossa syndrome: identifiable risk factors and irreversible complications. Pediatr Neurosurg. Sep 1999;31(3):131-6. [Medline].

  39. Healey EA, Barnes PD, Kupsky WJ, Scott RM, Sallan SE, Black PM. The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery. May 1991;28(5):666-71; discussion 671-2. [Medline].

  40. Carrie C, Mottolese C, Bouffet E, Negrier S, Bachelot TH, Lasset C. Non-metastatic childhood ependymomas. Radiother Oncol. Aug 1995;36(2):101-6. [Medline].

  41. McGuire CS, Sainani KL, Fisher PG. Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer. Jan 2009;52(1):65-9. [Medline].

  42. Amirian ES, Armstrong TS, Gilbert MR, Scheurer ME. Predictors of survival among older adults with ependymoma. J Neurooncol. Sep 28 2011;[Medline].

  43. Tomita T, McLone DG, Das L, Brand WN. Benign ependymomas of the posterior fossa in childhood. Pediatr Neurosci. 1988;14(6):277-85. [Medline].

  44. Sutton LN, Goldwein J, Perilongo G, Lang B, Schut L, Rorke L. Prognostic factors in childhood ependymomas. Pediatr Neurosurg. 1990-1991;16(2):57-65. [Medline].

  45. Jayawickreme DP, Hayward RD, Harkness WF. Intracranial ependymomas in childhood: a report of 24 cases followed for 5 years. Childs Nerv Syst. Jul 1995;11(7):409-13. [Medline].

  46. Pollack IF, Gerszten PC, Martinez AJ, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery. Oct 1995;37(4):655-66; discussion 666-7. [Medline].

  47. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg. Apr 1998;88(4):695-703. [Medline].

  48. Horn B, Heideman R, Geyer R, Pollack I, Packer R, Goldwein J. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol. May-Jun 1999;21(3):203-11. [Medline].

  49. Merchant TE, Mulhern RK, Krasin MJ, Kun LE, Williams T, Li C. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol. Aug 1 2004;22(15):3156-62. [Medline].

  50. Bailey P. Tumors arising from ependymal cells. Arch Neurol Psychiatr. 1924;11:1-27.

  51. Barnholtz-Sloan JS, Severson RK, Stanton B, Hamre M, Sloan AE. Pediatric brain tumors in non-Hispanics, Hispanics, African Americans and Asians: differences in survival after diagnosis. Cancer Causes Control. Jun 2005;16(5):587-92. [Medline].

  52. Bijlsma EK, Voesten AM, Bijleveld EH, et al. Molecular analysis of genetic changes in ependymomas. Genes Chromosomes Cancer. Aug 1995;13(4):272-7. [Medline].

  53. Birch BD, Johnson JP, Parsa A, et al. Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas. Neurosurgery. Jul 1996;39(1):135-40. [Medline].

  54. Duffner PK, Krischer JP, Sanford RA, Horowitz ME, Burger PC, Cohen ME. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg. Apr 1998;28(4):215-22. [Medline].

  55. Goldwein JW, Leahy JM, Packer RJ, et al. Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys. Dec 1990;19(6):1497-502. [Medline].

  56. Guyotat J, Signorelli F, Desme S, Frappaz D, Madarassy G, Montange MF. Intracranial ependymomas in adult patients: analyses of prognostic factors. J Neurooncol. Dec 2002;60(3):255-68. [Medline].

  57. Kramer DL, Parmiter AH, Rorke LB, et al. Molecular cytogenetic studies of pediatric ependymomas. J Neurooncol. Mar 1998;37(1):25-33. [Medline].

  58. Lyons MK, Kelly PJ. Posterior fossa ependymomas: report of 30 cases and review of the literature. Neurosurgery. May 1991;28(5):659-64; discussion 664-5. [Medline].

  59. Neumann E, Kalousek DK, Norman MG, et al. Cytogenetic analysis of 109 pediatric central nervous system tumors. Cancer Genet Cytogenet. Nov 1993;71(1):40-9. [Medline].

  60. Ransom DT, Ritland SR, Kimmel DW, et al. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes Cancer. Nov 1992;5(4):348-56. [Medline].

  61. Rogatto SR, Casartelli C, Rainho CA, Barbieri-Neto J. Chromosomes in the genesis and progression of ependymomas. Cancer Genet Cytogenet. Sep 1993;69(2):146-52. [Medline].

  62. Ross GW, Rubinstein LJ. Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg. Jan 1989;70(1):31-6. [Medline].

  63. Rubio MP, Correa KM, Ramesh V, et al. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res. Jan 1 1994;54(1):45-7. [Medline].

  64. Slavc I, MacCollin MM, Dunn M, et al. Exon scanning for mutations of the NF2 gene in pediatric ependymomas, rhabdoid tumors and meningiomas. Int J Cancer. Aug 22 1995;64(4):243-7. [Medline].

  65. Stratton MR, Darling J, Lantos PL, et al. Cytogenetic abnormalities in human ependymomas. Int J Cancer. Oct 15 1989;44(4):579-81. [Medline].

  66. Stüben G, Stuschke M, Kroll M, Havers W, Sack H. Postoperative radiotherapy of spinal and intracranial ependymomas: analysis of prognostic factors. Radiother Oncol. Oct 1997;45(1):3-10. [Medline].

  67. Tominaga T, Kayama T, Kumabe T, et al. Anaplastic ependymomas: clinical features and tumour suppressor gene p53 analysis. Acta Neurochir (Wien). 1995;135(3-4):163-70. [Medline].

  68. Vagner-Capodano AM, Gentet JC, Gambarelli D, et al. Cytogenetic studies in 45 pediatric brain tumors. Pediatr Hematol Oncol. Jul-Sep 1992;9(3):223-35. [Medline].

  69. Vanuytsel L, Brada M. The role of prophylactic spinal irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys. Aug 1991;21(3):825-30. [Medline].

  70. von Haken MS, White EC, Daneshvar-Shyesther L, et al. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer. Sep 1996;17(1):37-44. [Medline].

  71. Weremowicz S, Kupsky WJ, Morton CC, Fletcher JA. Cytogenetic evidence for a chromosome 22 tumor suppressor gene in ependymoma. Cancer Genet Cytogenet. Jul 15 1992;61(2):193-6. [Medline].

  72. Wernicke C, Thiel G, Lozanova T, et al. Involvement of chromosome 22 in ependymomas. Cancer Genet Cytogenet. Feb 1995;79(2):173-6. [Medline].

  73. Yates AJ. An overview of principles for classifying brain tumors. Mol Chem Neuropathol. Oct 1992;17(2):103-20. [Medline].

 
Previous
Next
 
CT scan without contrast. Fourth ventricle ependymoma.
CT scan without contrast. Fourth ventricle ependymoma. Note blood in the fourth ventricle.
CT scan without contrast in the patient with fourth ventricle ependymoma. Blood has refluxed into the third and lateral ventricles.
CT scan without contrast in the patient with fourth ventricle ependymoma. Note blood traversing foramina.
T1-weighted MRI. Rare case of a fourth ventricle ependymoma presenting as an intraventricular bleed.
T1-weighted MRI without contrast demonstrating ependymoma located in the fourth ventricle.
T2-weighted MRI demonstrating ependymoma in the fourth ventricle.
Coronal T1-weighted MRI with contrast demonstrating ependymoma of the fourth ventricle.
Gross surgical specimen of a fourth ventricle ependymoma.
Histologic study of a classic ependymoma. Note the characteristic perivascular pseudorosettes.
Cellular ependymoma. Cells with a high nuclear-cytoplasmic ratio. Few pseudorosettes or paucicellular areas are present.
Myxopapillary ependymoma. Clusters of loosely arranged cuboidal cells separated by pools of mucin.
Clear cell ependymoma. Round cells with cytoplasmic clearing. This may mimic an oligodendroglioma.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.